Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
89
resultados
Última actualización
18/03/2026 [07:14:00]
Resultados 50 a 75 de 89
Resumen de: MX2025014589A
The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).
Resumen de: MX2025011740A
An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 µg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-CoV-2, a heterogeneous SARS-CoV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.
Resumen de: MX2024009232A
The present application is in the field of genetic engineering, biotechnological and in particular in the design and production of synthetic genes in different strains of Escherichia coli resulting in soluble molecules with antigenic capacity against the SARS-CoV2 virus. This method is summarized in three phases which are: The application of molecular engineering for obtaining the DNA sequence that allows E coli to produce SARS-CoV2 viral antigens, followed by integration of the designed vector into E coli cells to obtain recombinant strains and finally the production and purification of recombinant viral antigens of SARS-CoV2 in E coli.
Resumen de: NZ791834A
Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject.
Resumen de: RS20240787A1
Method and device for applying an electrical stimulus to an acupuncture point using an electrode connected to ground on a patient exposed to the emitted electromagnetic field of a Tesla transformer. The intention of the invention is increasing the effectiveness of acupuncture treatment, while making its use painless for the general population, and especially suitable for the pediatric population. The device can be used to relieve symptoms and pain caused by trauma, post-Covid 19 syndrome, for prevention of worsening of such symptoms, for the prevention and treatment of symptoms associated with depression and other psychiatric, neurological and developmental disorders, including major depressive disorder, Alzheimer's disease and autism. The device consists of a Tesla transformer (1) and an electrode or set of electrodes (6) connected to an electrical ground (4). The Tesla transformer (1) consists of a primary coil (1.a), a secondary coil (1.b), a feedback coil (1.c) and a control circuit (2). The system also includes a variable resistor (7), which regulates the radiation intensity of the Tesla transformer (1).
Resumen de: AU2024335376A1
The present disclosure relates to in vitro identification of neutralizing antibody against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Specifically, the present disclosure relates a kit and an in vitro assay for analyzing the presence of neutralizing antibody/inhibitors which could block or inactivate receptor binding domain of the spike protein of SARS-CoV-2.
Resumen de: US20260028644A1
Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.
Resumen de: US20260028685A1
In one aspect, the inventive technology relates to improved systems, methods, and compositions for a novel saliva stabilization solution for use in nucleic acid amplification reactions, and in particular embodiment its use in the detection of pathogen nucleic acids, such as SARS-CoV-2 (COVID-19).
Resumen de: US20260028673A1
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to global public health. While some individuals exhibit mild symptoms, others develop severe disease leading to severe lymphopenia and death. Provided herein are methods for determining whether a subject suffering from a SARS-Cov-2 infection is more likely to suffer from severe or mild disease. Also provided are methods for predicting whether a subject suffering from a SARS-Cov-2 infection with mild disease will progress to more severe disease and methods for treating patients having an infection via SARS-Cov-2 and related family members.
Resumen de: US20260029316A1
An immunochromatographic method for a trace amount of an antigen or an antibody such as SARS-COV-2 including use of saliva, enabling highly sensitive immunochromatographic antigen or antibody detection even when the saliva is used. A method for pretreatment of a specimen for an immunochromatographic test, including passing the saliva through a porous member capable of supporting a viscous component in the saliva to remove the viscous component, passing the liquid that has passed through the porous member through a filter having a hole diameter of from 0.1 μm to 10 μm, and concentrating an antigen or an antibody in the liquid that has passed through the filter.
Resumen de: WO2026021236A1
Provided are a polypeptide capable of inhibiting a MERS-like coronavirus infection, and a use thereof. On the basis of a membrane fusion invasion feature mediated by an S2 subunit of a MjHKU4r-CoV coronavirus S protein, a group of polypeptides are invented by using the HR1 functional domain of the protein as a target. The polypeptides can efficiently inhibit the membrane fusion invasion process of a MERS-like coronavirus MjHKU4r-CoV. By competitively binding to a viral HR1 functional domain, these polypeptides inhibit the formation of a viral 6-helix bundle (6-HB) fusion core, thereby efficiently blocking the process of the coronavirus MjHKU4r-CoV invading a target cell. The present invention can provide an efficient preventive and therapeutic candidate drug for prevention and treatment of the MERS-like coronavirus MjHKU4r-CoV having potential high pathogenicity and cross-species transmission.
Resumen de: WO2026023869A1
The present application relates to a vaccine composition comprising peptides isolated from structural proteins of SARS-CoV-2.
Resumen de: WO2026023870A1
The present application relates to a method for extracting epitopes effective in the prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising the steps of: (a) extracting, from an anti-spike antibody database, first structural data including known structures and second structural data including unknown structures, and extracting, from a SARS-CoV-2 proteome database, third structural data including known structures; (b) carrying out 3D modeling on the second structural data, and classifying the third structural data into a first group including structural proteins and a second group including both structural proteins and non-structural proteins; (c) carrying out spike-antibody docking on the basis of the first group and the second structural data on which 3D modeling has been carried out; (d) constructing a spike-antibody database on the basis of the first structural data and the docked data, and predicting conformational epitopes on the basis of the second group; (e) characterizing epitopes on the basis of the spike-antibody database and the conformational epitopes; and (f) selecting final epitopes on the basis of analysis results.
Resumen de: EP4684778A1
Provided is a pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and an auxiliary material. The auxiliary material comprises one or more of a filler, a binder, a glidant, a disintegrant and a lubricant. The pharmaceutical composition has the feasibility of preparation process, excellent properties of preparations, good stability and good dissolution, and meets the pharmaceutical standards.
Resumen de: CN121378462A
The invention discloses a neutralizing antibody THC4555 for neutralizing SARS-CoV-2 in a broad spectrum and an application of the neutralizing antibody THC4555. The invention provides an IgG (immunoglobulin G) antibody (named as THC4555 antibody) of spike protein specifically combined with SARS-CoV-2. The IgG antibody consists of a light chain and a heavy chain, cDR1, CDR2 and CDR3 in a heavy chain variable region in the heavy chain are sequentially as shown in 26th to 33rd sites, 51st to 58th sites and 97th to 116th sites in SEQ ID NO: 1; cDR1, CDR2 and CDR3 in a light chain variable region in the light chain are sequentially shown as the 26th to 33rd sites, the 51st to 53rd sites and the 90th to 100th sites in SEQ ID NO: 4. The THC4555 antibody has the effect of neutralizing the SARS-CoV-2 in a broad spectrum, and has application value in prevention and control of the novel coronavirus.
Resumen de: CN121378408A
The invention belongs to the technical field of biological medicine, and particularly relates to application of polypeptide in distinguishing infection of novel coronavirus (SARS-CoV-2) with different severity degrees, and the polypeptide is KTFPPTEPKKDKKKK (SEQ ID NO: 1) and/or ALPQRQKKQQTVTLL (SEQ ID NO: 2). By detecting the abundance of the IgA antibody combined with the polypeptide, the severity of the SARS-CoV-2 infected patient can be effectively distinguished.
Resumen de: CN121378497A
The invention discloses a bispecific fully humanized single-domain antibody targeting a novel coronavirus and CD16a and an application of the bispecific fully humanized single-domain antibody. The antibody comprises a single-domain antibody n3130v targeting a novel coronavirus and a single-domain antibody n118 targeting a human CD16a, the amino acid sequence of the n3130v is as shown in SEQ ID NO: 1, and the amino acid sequence of the n118 is as shown in SEQ ID NO: 2. The antibody disclosed by the invention has the capabilities of broad-spectrum recognition and neutralization of novel coronavirus, can be efficiently combined with a CD16a target spot, and is used for mediating antibody-dependent cell-mediated cytotoxic action (ADCC). The bispecific antibody can be used for novel coronavirus related research and treatment of diseases caused by novel coronavirus infection.
Resumen de: CN121378463A
The invention belongs to the technical field of biological medicine, and particularly relates to a detection kit for detecting new coronavirus. According to the invention, a new coronavirus NP protein is taken as an immunogen, monoclonal antibodies aiming at specific epitopes of the new coronavirus NP protein are screened, a specific strain is taken as a capture antibody, the other strain is labeled by horse radish peroxidase and taken as a detection antibody, and a double-antibody sandwich ELISA method for detecting the SARS-CoV-2 NP protein is established. Compared with the prior art, the method has the advantages that the detection time is greatly shortened, the detection can be completed in only 6 hours, and a foundation is laid for rapid detection of an SARS-CoV-2 clinical sample.
Resumen de: CN121380126A
The invention discloses a construction and verification method of an HEK293T cell line capable of stably overexpressing human ANT2, which comprises the following steps: cloning a human ANT2 gene, constructing the human ANT2 gene into a lentivirus expression plasmid pLVX-TRE3G, co-transfecting the lentivirus expression plasmid pLVX-TRE3G and a helper plasmid pLVX-Tet3G into an HEK293T-ACE2 cell, and carrying out puromycin and G418 pressurized screening and Western blot identification to obtain the HEK293T cell line capable of stably overexpressing human ANT2. A result shows that the expression quantity of the ANT2 is the highest when the HEK293T-ACE2-ANT2 cell is induced for 12 hours at the Doxycycline of 6mg/L; when the ANT2 is induced to express, the virus nucleic acid load and the N protein expression level after SARS-CoV-2 infection are obviously reduced, which indicates that the ANT2 has an inhibition effect on SARS-CoV-2 infection replication, and a cell model and an experimental basis are provided for exploring the effect of the ANT2 in virus infection resistance.
Resumen de: CN121385327A
The invention belongs to the technical field of medical detection, and particularly relates to application of an SOUL protein detection reagent in preparation of a novel coronavirus infection screening kit and the screening kit. According to the invention, the neutrophile granulocyte SOUL protein in alveolar lavage fluid is used as the biomarker for screening and detecting novel coronavirus infection for the first time. The kit for detecting the neutrophile granulocyte SOUL protein in the alveolar lavage fluid is provided by optimizing the composition of the kit and the detection method, the content of the neutrophile granulocyte SOUL protein in the alveolar lavage fluid can be rapidly and accurately detected by applying the detection kit disclosed by the invention, the discrimination of light symptom and severe symptom classification of novel coronavirus infection is realized, and the accuracy and the accuracy of detection of the neutrophile granulocyte SOUL protein in the alveolar lavage fluid are improved. The method has a good application prospect in detection and treatment of novel coronavirus infection diseases.
Resumen de: CN121399105A
The present invention relates to novel dihydroorotate dehydrogenase (DHODH) inhibitors of formula (I) having carboxylic acid, carboxamide or bioisostere moieties and optionally deuterated, pharmaceutical formulations comprising them, their process of preparation and their use as a medicament, alone or in combination with one or more other agents, for the treatment of various diseases in which inhibition of DHODH is desired, such as SARS-CoV-2 or IDH mutant cancers.
Resumen de: US20260022379A1
Described are optimized RNAi agents, compositions that include RNAi agents, and methods for inhibition of coronavirus (CoV) viral genome. The optimized CoV RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a SARS-CoV-2 viral genome, and the targeted portions of the genome are conserved across a variety of known coronaviruses. Pharmaceutical compositions that include one or more optimized CoV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described CoV RNAi agents to pulmonary cells, in vivo, provides for inhibition of CoV viral genome expression, including SARS-CoV-2, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including COVID-19.
Resumen de: US20260021204A1
The present disclosure relates to anti-SARS-COV-1 and anti-SARS-COV-2 activatable RNase guide sequences and methods of use for screening, treating, and/or preventing SARS infections and/or COVID-related diseases.
Resumen de: WO2026017760A1
5 A composition in oral dosage form comprises tryptophan or at least one tryptophan intermediate, and at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and/or (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. The composition may include a cohort of bacteria 10 including at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and at least one bacterium that (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. Typically, the cohort of bacteria is capable of producing the immunomodulatory indole derivatives indole-3-lactic acid (ILA), 15 indole-3-propionic acid (IPA) and indole acrylic acid (IA). The composition finds utility in inhibition or prevention of immune-mediated inflammatory damage in subjects with an immune-mediated infectious or non-infectious disease, and in particular can prevent a severe inflammatory response or incidence of Long Covid in SARS-CoV-19 subjects. 20 (Figure 16)
Nº publicación: NL2039943A 22/01/2026
Solicitante:
UNIV SHANXI [CN]
SHANXI UNIVERSITY
Resumen de: NL2039943A
The invention relates to the technical field of biopharmaceuticals, in particular to an application of a dual-target polypeptide for simultaneously inhibiting the activities of Furin and Mpro in the prevention and treatment of COVID-19. In order to provide a polypeptide with inhibitory activity on Furin and Mpro at the same time, the 42nd, 45th and 46th amino acids of Eglin C are mutated at site to obtain Eglin C mutants. According to the research of the invention, it is found that the Eglin C mutant can significantly inhibit the activities of Furin protease and Mpro protease. The Eglin C mutant provides a new research direction and idea for the development of polypeptide drugs for preventing and treating Covid-19.
BOPI
Sede Electrónica
